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ABSTRACT
This study investigated the association between
prescription of ﬂuoroquinolones and emergence
of ciproﬂoxacin resistance among Escherichia coli
isolates in the urine of outpatients from whom a
ciproﬂoxacin-sensitive E. coli strain had been iso-
lated previously. Patients were identiﬁed and
followed using the healthcare databases of Emil-
ia-Romagna Region, Italy. The outcome of interest
was the ﬁrst isolation from urine of an E. coli
strain resistant to ciproﬂoxacin. Prescription of
ﬂuoroquinolones during the previous 6 months
was associated independently with the emergence
of ciproﬂoxacin resistance; the strength of the
association varied according to individual ﬂuor-
oquinolone agents.
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The prevalence of resistance to ﬂuoroquinolones
among Escherichia coli isolates from urine in
Emilia-Romagna (a northern region of Italy with
4 million inhabitants) was 16.4% in 2003 and
17.2% in 2004 [1]. Human consumption of ﬂuor-
oquinolones in the community in Emilia-Romag-
na was 2.3 deﬁned daily doses (DDDs) ⁄ 1000
inhabitant-days in 2003 and 2.2 DDDs ⁄ 1000
inhabitant-days in 2004; the agents prescribed
most frequently in 2004 were levoﬂoxacin, ci-
proﬂoxacin, norﬂoxacin and moxiﬂoxacin (39%,
30%, 11% and 11% of total ﬂuoroquinolone
DDDs, respectively) (unpublished data). The
aim of the present study was to investigate the
association between prescription of ﬂuoroquino-
lones and emergence of ciproﬂoxacin resistance
among E. coli isolates in the urine of outpatients
from whom a ciproﬂoxacin-sensitive E. coli strain
had been isolated previously.
Data for the study were obtained from the
antimicrobial resistance surveillance system of
Emilia-Romagna, as well as databases concerning
patterns of care in the resident population, home
care andmortality. Criteria for inclusion of patients
in the study were: age ‡18 years; residence in
Emilia-Romagna; one or more urine cultures pos-
itive for E. coli during 2003–2004, with antibiotic
susceptibility data available; and a ﬁrst (or only)
E. coli isolate that was sensitive to ciproﬂoxacin,
and that grew from an outpatient urine sample.
The outcome of interest was the ﬁrst isolation of a
ciproﬂoxacin-resistant E. coli from an outpatient
urine sample. E. coli isolates with ciproﬂoxacin
MICs £1 mg ⁄L, or ciproﬂoxacin zone diameters
‡21 mmwith a 5-lg disk, were deﬁned as suscept-
ible, while strains with ciproﬂoxacin MICs
‡4 mg ⁄L, or ciproﬂoxacin zone diameters
£15 mm, were deﬁned as resistant [2]. The date of
entry into the cohort was the date onwhich the ﬁrst
sample (ciproﬂoxacin-susceptible) was received.
Patients were followed until 31 December 2004;
follow-up ended with the ﬁrst isolation of a
ciproﬂoxacin-resistant E. coli isolate, death, admis-
sion to hospital, or referral to the home care service.
Using the cohort as a base, all subjects were
included in a case-control study and were
considered as cases if a ciproﬂoxacin-resistant
E. coli strain had been isolated during follow-up.
The date of selection for the case-control study
corresponded with the day of exit from the
cohort or with the end of follow-up. All systemic
antibiotics (J01 Anatomic Therapeutical Chemical
Group (ATC); http://www.whocc.no/ateddd/)
prescribed during follow-up were considered
and grouped, according to the ATC, as ﬂuoro-
quinolones (further catagorised as ciproﬂoxacin,
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norﬂoxacin, levoﬂoxacin and other ﬂuoroquino-
lones), other quinolones, cephalosporins, exten-
ded-spectrum penicillins, penicillins ⁄ b-lactamase
inhibitors, macrolides, nitrofurantoin, fosfomy-
cin, trimethoprim–sulphamethoxazole, tetracy-
clines, aminoglycosides, or other agents.
Exposure to one group of antibiotics was cate-
gorised according to the period between the date
of selection for the case-control study and the
date of the last prescription of an agent belong-
ing to that group (patients who were prescribed
an agent within 180 days before the date of
selection were regarded as exposed). Other
variables considered were gender, age at time
of selection for the case-control study, duration
of follow-up, number of relapses ⁄ re-infections
with non-resistant strains of E. coli isolated from
urine during follow-up, and the local health
trust of the laboratory.
STATA v.8.0 (Stata Corp., College Station, TX,
USA) was used for analysis, with p 0.05 consid-
ered signiﬁcant. Univariate analysis was conduc-
ted by Poisson regression. For the case-control
study, categorical variables were compared using
chi-square tests or Fisher exact tests, as appropri-
ate, while Student’s t-test was used for quantita-
tive variables. Multivariate analysis was
performed with unconditional logistic regression
using the likelihood ratio test.
The study population comprised 11 428 sub-
jects with isolation of community-acquired E. coli
from urine. Urine cultures were processed by ten
laboratories in Emilia-Romagna that belonged to
eight of the 16 local health trusts of the region.
The overall isolation rate of ciproﬂoxacin-resistant
E. coli was 23 ⁄ 1000 person-years, but was higher
for older individuals and for those with relap-
ses ⁄ re-infections caused by non-resistant strains
during follow-up. Local health trusts were asso-
ciated signiﬁcantly with the outcome, but no
association was observed with the calendar per-
iod (semesters of follow-up).
ORs for isolation of resistant E. coli decreased,
with an increasing period between the last pre-
scription of ﬂuoroquinolones and the date of
selection for the case-control study (Fig. 1). In the
multivariate analysis, prescription of ﬂuoroqui-
nolones during the previous 180 days was asso-
ciated signiﬁcantly with isolation of resistant
E. coli from urine; the strength of the association
varied according to the individual agents (the
highest OR was observed for ciproﬂoxacin),
suggesting a different potential for selection of
resistance. Other independent variables associ-
ated with the outcome were prescription of
penicillins ⁄ b-lactamase inhibitors or cephalospo-
rins, relapses ⁄ re-infections caused by non-resist-
ant strains during the follow-up, older age
categories, duration of follow-up, female gender,
and the local health trust of the laboratory
(Table 1). The associations between prescription
of penicillins ⁄ b-lactamase inhibitors and cephalo-
sporins, and the emergence of resistance to
ciproﬂoxacin in E. coli, could be related to the
observed presence of co-resistance between these
agents and ciproﬂoxacin. The increased risk of
resistance in subjects with relapses ⁄ re-infections
can be explained by the measure of exposure to
infection by uropathogens, including ciproﬂoxa-
cin-resistant E. coli, which is provided by this
variable.
A limitation of the study was the absence of
clinical information concerning the severity of the
infection and ⁄ or the presence of complicating
conditions. Moreover, data concerning prescrip-
tions from the private sector were not recorded in
the database, leading to a possible underestimate
of exposure to antibiotics, which could bias ORs
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Fig. 1. Association between previ-
ous use of ﬂuoroquinolones and
emergence of ciproﬂoxacin resist-
ance among Escherichia coli isolates
from urine. Previous use of ﬂuoro-
quinolones was categorised accord-
ing to the time of the last
prescription before the date of
selection for the case-control study.
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towards a value of 1. Another potential limitation,
which could similarly bias the ORs, is the mis-
classiﬁcation of a proportion of cases as controls
when a microbiological diagnosis of the resistant
infection was either not performed or was per-
formed at a laboratory not included in the
regional surveillance system [3]. Finally, the
number of ciproﬂoxacin-susceptible E. coli iso-
lates after entry into the cohort is only a proxy
variable that probably underestimates the real
frequency of relapses ⁄ re-infections, as not all
urinary tract infections are cultured, or culture
occurs in laboratories not included in the regional
surveillance system. An underestimate of the
number of relapses ⁄ re-infections could prevent
full elimination of the positive confounding effect
caused by the exposure, leading to an overesti-
mate of the ORs for the association between
previous prescription of ﬂuoroquinolones and the
emergence of resistance to ciproﬂoxacin.
Nevertheless, the study cohort was a well-
deﬁned population that was not initially infected
by ciproﬂoxacin-resistant E. coli, and for which
infections diagnosed during follow-up were very
unlikely to be healthcare-related. The recorded
data also allowed adjustment for the duration of
follow-up [4]. The results showed a strong associ-
ation between previous prescriptions of ﬂuoro-
quinolones and the emergence of resistance to
ciproﬂoxacin in E. coli from community-acquired
urinary tract infections. Fluoroquinolones should
thus be used prudently, avoiding unnecessary
prescriptions and considering alternative regi-
mens both for urinary tract and for respiratory
tract infections. The increased risk of E. coli
resistance to ciproﬂoxacin in patients with a
history of recent treatment with ﬂuoroquinolones
could be considered a criterion for choosing an
alternative therapy for community-acquired urin-
ary tract infections.
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ABSTRACT
In total, 129 Plasmodium vivax isolates from
different geographical areas in India were ana-
lysed for point mutations in the P. vivax di-
hydrofolate reductase gene that were associated
with pyrimethamine resistance. A gradual
increase in the frequency of mutant genotypes
was observed from north to south (p <0.0001).
In the northern region (Delhi, Panna and
Nadiad), the wild-type genotype was most
prevalent, while the mutant genotype predom-
inated in the coastal regions of southern India
(Navi Mumbai, Goa and Chennai). Isolates from
the Car-Nicobar islands showed only mutant
genotypes. The differential geographical pattern
of mutations may be associated with the trans-
mission pattern.
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The worldwide spread of chloroquine-resistant
strains of Plasmodium falciparum has led to the use
of sulphadoxine–pyrimethamine as the ﬁrst-line
anti-malarial agent in south-east Asian countries.
Sulphadoxine and pyrimethamine sequentially
inhibit the dihydropteroate synthase (Dhps) and
dihydrofolate reductase (Dhfr) enzymes, respect-
ively, in the folate biosynthesis pathway to give a
synergic anti-malarial effect [1]. However, P. fal-
ciparum has overcome the effect of sulphadoxine–
pyrimethamine by evolving point mutations in
the genes encoding the Dhps and Dhfr enzymes
that reduce their drug-binding afﬁnity [2,3]. In
India, chloroquine remains the ﬁrst-line anti-
malarial agent for treatment of both P. falciparum
and Plasmodium vivax. Chloroquine resistance in
P. falciparum has been reported in India [4,5], and
areas with a chloroquine resistance level of >25%
have switched to the use of sulphadoxine–
pyrimethamine as the ﬁrst-line anti-malarial
agent. Although P. vivax is still susceptible to
chloroquine in India [6,7], the use of sulphadox-
ine–pyrimethamine to treat chloroquine-resistant
P. falciparum is creating selection pressure in the
P. vivax population. Therefore, the aim of the
present study was to obtain information concern-
ing mutations related to pyrimethamine resist-
ance in the P. vivax dhfr gene of Indian ﬁeld
isolates.
A previous study [8] identiﬁed six new muta-
tions in the P. vivax dhfr gene by sequencing, but
nonewas located in the active sites [9]. Therefore, in
order to screen ﬁeld isolates for P. vivax dhfr
Corresponding author and reprint requests: H. Joshi, National
Institute of Malaria Research (ICMR), 22-Sham Nath Marg,
Delhi-110 054, India
E-mail: hema_joshi_mrc@yahoo.com
Research Notes 331
 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 316–346
